The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
New Guideline on Vaccination Recommendations for Patients with Rheumatic and Musculoskeletal Disease
August 3rd 2022The new treatment guideline addressed the possibility of differing safety and effectiveness outcomes among patients with rheumatic and musculoskeletal disease regarding vaccination compared with the general population.
Decreased Length of Stay After Total Joint Arthroplasty Predicted by Sleep Quality
July 29th 2022Patients with high preoperative sleep quality, high preoperative albumin level, free of digestive disease and undergoing total hip arthroplasty procedure are more likely to be discharged within 2 days as opposed to 3.
Phase 3 Secukinumab Data Supports EC Approval for Patients with JIA, ERA, JPsA
July 11th 2022Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Investigators Call for More Research on Juvenile Arthritis and Exposure to Maternal Infection
July 11th 2022A new study revealed no significant relationship between patients with juvenile idiopathic arthritis and exposure to maternal infection, however, investigators said that suggestive evidence of differential sex-specific results indicate a need for further study.
Philip Mease, MD: Achieving Goals in Psoriatic Arthritis Treatment
July 6th 2022Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.
Philip Mease, MD: Guselkumab Addresses the Complexities of Treating Psoriatic Arthritis
July 1st 2022With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.
Improve Shared Decision Making Between Providers and Patients with Rheumatic Disease
June 1st 2022Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.